Evidence map›Paper›PMID 26367234›Full record

Trial reportBone marrow transplantation2016

UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation.

N Santos, R Rodríguez-Romanos, J B Nieto, I Buño, C Vallejo, A Jiménez-Velasco, S Brunet, E Buces, J López-Jiménez, M González and 6 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. SNPs and prognosis of GvHD before HCT: any progress?Bone marrow transplantation · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 1 country.

N SantosClinical Hematology Department, Institut Català d'Oncologia, IDIBGi, Girona, Spain.
R Rodríguez-RomanosClinical Hematology Department, Institut Català d'Oncologia, IDIBGi, Girona, Spain.
J B NietoHematology Department, Hospital Morales Meseguer, Murcia, Spain.
I BuñoHematology Department, Hospital Gregorio Marañón, Madrid, Spain.
C VallejoHematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
A Jiménez-VelascoHematology Department, Hospital Carlos Haya, Málaga, Spain.
S BrunetHematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
E BucesHematology Department, Hospital Gregorio Marañón, Madrid, Spain.
J López-JiménezHematology Department, Hospital Ramón y Cajal, Madrid, Spain.
M GonzálezHematology Department, Hospital Universitario, Salamanca, Spain.
C FerráInstitut Català d'Oncologia, Badalona, Spain.
A SampolHematology Department, Hospital Son Espases, Palma de Mallorca, Spain.
R de la CámaraHematology Department, Hospital La Princesa, Madrid, Spain.
C MartínezHematology Department, Hospital Clínic, Barcelona, Spain.
D GallardoClinical Hematology Department, Institut Català d'Oncologia, IDIBGi, Girona, Spain.
GvHD/Immunotherapy Working Party of the Spanish Group of Hematopoietic Transplant (GETH)
Institut Català d'Oncologia · ESHospital General Universitario Gregorio Marañón · ESComplejo Hospitalario de Salamanca · ESHospital Clínic de Barcelona · ESHospital de Sant Pau · ESHospital Doctor José Molina Orosa · ESHospital General Universitario Morales Meseguer · ESHospital Universitario Central de Asturias · ESHospital Universitario de La Princesa · ESHospital Universitario Ramón y Cajal · ESHospital Universitario Son Espases · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Minor histocompatibility Ags (mHags) have been implicated in the pathogenesis of GVHD after allogeneic hematopoietic stem cell transplantation (HSCT). Uridine diphospho-glucuronosyltransferase 2B17 (UGT2B17) gene deletion may act as a mHag and its association with acute GVHD (aGVHD) has been described. We retrospectively studied the clinical impact of a UGT2B17 mismatch in a cohort of 1127 patients receiving a HSCT from an HLA-identical sibling donor. UGT2B17 mismatch was present in 69 cases (6.1%). Incidence of severe aGVHD was higher in the UGT2B17 mismatched pairs (22.7% vs 14.6%), but this difference was not statistically significant (P: 0.098). We did not detect differences in chronic GVHD, overall survival, relapse-free survival, transplant-related mortality or relapse. Nevertheless, when we analyzed only those patients receiving grafts from a male donor (616 cases), aGVHD was significantly higher in the UGT2B17 mismatched group (25.1% vs 12.8%; P: 0.005) and this association was confirmed by the multivariate analysis (P: 0.043; hazard ratio: 2.16, 95% confidence interval: 1.03-4.57). Overall survival was worse for patients mismatched for UGT2B17 (P: 0.005). We conclude that UGT2B17 mismatch has a negative clinical impact in allogeneic HSCT from HLA-identical sibling donors only when a male donor is used. These results should be confirmed by other studies.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHLA AntigensSiblingsTissue DonorsAcute DiseaseAdolescentAdultAgedAllograftsChildChild, PreschoolDisease-Free SurvivalFemaleGlucuronosyltransferaseHumansGlucuronosyltransferaseHLA AntigensUGT2B7 protein, human

Identifiers

PMID26367234
OpenAlexW2293344994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.